Alcon, the global leader in eye care, recently acquired Ivantis, Inc. and its Hydrus Microstent,1 a minimally invasive glaucoma surgery (MIGS) device. The Hydrus Microstent is a next-generation MIGS device designed to reduce eye pressure by re-establishing flow through Schlemm’s canal, the eye’s natural outflow pathway. When placed in the canal during minimally invasive microsurgery, the device restores the flow of fluid in the eye, using a tri-modal mechanism of action: the Hydrus Microstent dilates and scaffolds Schlemm’s canal to augment outflow of aqueous humor from the anterior chamber. Hydrus Microstent is one of the most rigorously researched and thoroughly studied MIGS devices. Hydrus Microstent is registered in Australia to treat patients with primary open-angle glaucoma in conjunction with cataract surgery and as a standalone surgery. The five-year HORIZON clinical study of Hydrus Microstent is the longest, continuous follow-up of a MIGS device.
It demonstrated that over 65% of Hydrus Microstent patients remained medication-free at five years compared to cataract surgery alone.2 The results also showed over 60% reduction in risk of invasive secondary glaucoma surgeries compared to cataract surgery alone – and its safety profile was sustained through the five-year follow-up.3
Contact: Alcon (AUS) 1800 224 153 (NZ) 0800 101 106 ANZ-HDM-2200003.
References
- www.alcon.com/media-release/alcon-completes-acquisition-ivantis-inc-bringing-hydrus-microstent-its-global (ABOUT Hydrus Microstent)
- Ahmed, I.K. (2021, Mar. 4-7). 5 Year Follow Up from the HORIZON Trial. American Glaucoma Society Virtual Annual Meeting. www.ivantisinc.com/clinical-evidence/ (p=0.001)
- Ahmed, I.K. (2021, Mar. 4-7). 5 Year Follow Up from the HORIZON Trial. American Glaucoma Society Virtual Annual Meeting. www.ivantisinc.com/clinical-evidence/ (p=0.022)
